You are currently viewing a new version of our website. To view the old version click .
Proceedings
  • Abstract
  • Open Access

25 September 2025

Digoxin as a Potential Anticancer Agent in Melanoma Treatment †

,
,
,
and
1
Faculty of Pharmacy, “Victor Babeș” University of Medicine and Pharmacy from Timisoara, 2 Eftimie Murgu Square, 300041 Timișoara, Romania
2
Research Centre for Pharmaco-toxicological Evaluations, “Victor Babeș” University of Medicine and Pharmacy from Timișoara, 2 Eftimie Murgu Square, 300041 Timișoara, Romania
3
Biocatalysis Group, Department of Applied Chemistry and Engineering of Organic and Natural Compounds, Faculty of Industrial Chemistry and Environmental Engineering, Politehnica University Timisoara, Carol Telbisz 6, 300001 Timisoara, Romania
*
Author to whom correspondence should be addressed.
This article belongs to the Proceedings International Conference on Interdisciplinary Approaches and Emerging Trends in Pharmaceutical Doctoral Research: Innovation and Integration
Cutaneous melanoma (CM) is one of the most aggressive and lethal forms of skin cancer, characterized by a high rate of proliferation, marked local invasion, and high metastatic potential. The incidence of this type of cancer has increased significantly in recent decades, especially among the Caucasian population, which is frequently exposed to ultraviolet radiation. Although early diagnosis can lead to favorable survival rates, advanced forms of melanoma continue to pose major therapeutic challenges, particularly due to acquired resistance to standard therapies and rapid disease recurrence. In this context, oncological research has increasingly focused on repositioning existing drugs, especially those of natural origin, known for their clinical safety and well-established pharmacological profile [,]. One such compound is digoxin (Dgx), a cardiac glycoside extracted from the plant Digitalis purpurea, which has been used for over two centuries in the treatment of heart failure and arrhythmias []. Recently, Dgx has attracted the attention of researchers due to its antitumor effects, demonstrated in multiple experimental models, including melanoma cells [] and ovarian cancer cells [].
The present work was designed to evaluate the anticancer activity of Dgx as a potential alternative treatment for CM. The investigations were conducted on the A375 cell line, selected as an in vitro 2D experimental model for CM. Assessment of the cytotoxic potential of Dgx (75, 100, 125, 150, and 200 nM) was performed through a series of experiments on A375 cells, including determination of cell viability using the MTT technique, analysis of cell morphology and confluence, and examination of cell nuclei by staining with Hoechst 33,342 after a 24 h treatment. The results indicated that Dgx decreases the viability of CM cells in a dose-dependent manner (up to approximately 46%). The morphological cell analysis revealed a similar trend whereby increasing concentrations of Dgx enhanced the presence of dismorphologies (cell rounding, cell constriction, cell detachment from the plaque). In the same manner, cell confluency decreased with rising doses, confirming the dose-dependent effect of Dgx. In addition, staining with Hoechst 33,342 confirmed that the concentration of 200 nM Dgx induces apoptotic-like nuclear changes (such as nuclear condensation, nuclear shrinkage, and reduction in nuclear size).
In light of these findings, this study provides further support for the repositioning of Dgx as a potential adjuvant therapy for CM. In order to expand on these studies, investigating the exact mechanism of action, determining the impact in healthy experimental models, and verifying the biosafety profile will be fundamental aspects to explore. Future research directions include analyzing Dgx in other types of cancers, such as ovarian, breast, and prostate cancer, given the versatile biological properties that make this compound a potential candidate for alternative cancer treatments.

Author Contributions

Conceptualization, Ș.-I.D. and C.-A.D.; methodology, Ș.-I.D. and A.C.; software, A.S. and S.L.; validation, Ș.-I.D. and C.-A.D.; formal analysis, S.L.; investigation, Ș.-I.D.; resources, A.C.; data curation, A.S.; writing—original draft preparation, Ș.-I.D.; writing—review and editing, Ș.-I.D. and C.-A.D.; visualization, A.S. and A.C.; supervision, S.L.; project administration, S.L.; funding acquisition, C.-A.D. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by “Victor Babeș” University of Medicine and Pharmacy.

Institutional Review Board Statement

Not applicable.

Data Availability Statement

Data are contained within the article.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Schadendorf, D.; Fisher, D.E.; Garbe, C.; Gershenwald, J.E.; Grob, J.J.; Halpern, A.; Herlyn, M.; Marchetti, M.A.; McArthur, G.; Ribas, A.; et al. Melanoma. Nat. Rev. Dis. Primers 2015, 1, 1–20. Available online: https://www.nature.com/articles/nrdp20153 (accessed on 20 June 2025). [CrossRef] [PubMed]
  2. Conforti, C.; Zalaudek, I. Epidemiology and Risk Factors of Melanoma: A Review. Dermatol. Pract. Concept. 2021, 11 (Suppl. 1), e2021161S. Available online: https://pmc.ncbi.nlm.nih.gov/articles/PMC8366310/ (accessed on 20 June 2025). [CrossRef] [PubMed]
  3. Zhao, S.; Li, X.; Wu, W.; Liu, S.; Shen, M.; Zhang, Z.; He, J. Digoxin reduces the incidence of prostate cancer but increases the cancer-specific mortality: A systematic review and pooled analysis. Andrologia 2021, 53, e14217. [Google Scholar] [CrossRef] [PubMed]
  4. Rednic, R.; Macasoi, I.; Pinzaru, I.; Dehelean, C.A.; Tomescu, M.C.; Susan, M.; Feier, H. Pharmaco-Toxicological Assessment of the Combined Cytotoxic Effects of Digoxin and Betulinic Acid in Melanoma Cells. Life 2022, 12, 1855. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  5. Chou, J.C.; Li, J.H.; Chen, C.C.; Chen, C.W.; Lin, H.; Wang, P.S. Inhibitory Effects of Digoxin and Digitoxin on Cell Growth in Human Ovarian Cancer Cell Line SKOV-3. Integr. Cancer Ther. 2021, 20, 15347354211002662. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.